# A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

> **NCT03496207** · PHASE2 · COMPLETED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 106 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Placebo
- **DRUG:** Sotatercept
- **OTHER:** SOC

## Key facts

- **NCT ID:** NCT03496207
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-13
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496207, "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03496207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*